359 related articles for article (PubMed ID: 16897969)
21. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
[TBL] [Abstract][Full Text] [Related]
22. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
23. [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].
Morimoto S; Shono Y; Tsuji T; Makihara K; Kawato N; Hachino Y; Mishima H; Tsujinaka T; Tabuse K
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2083-9. PubMed ID: 14712769
[TBL] [Abstract][Full Text] [Related]
24. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
Ohtsu A; Baba H; Sakata Y; Mitachi Y; Horikoshi N; Sugimachi K; Taguchi T
Br J Cancer; 2000 Jul; 83(2):141-5. PubMed ID: 10901361
[TBL] [Abstract][Full Text] [Related]
26. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
27. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Yamagata S; Nakata B; Hirakawa K
Oncol Rep; 2004 Nov; 12(5):973-8. PubMed ID: 15492780
[TBL] [Abstract][Full Text] [Related]
28. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Schöffski P
Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
[TBL] [Abstract][Full Text] [Related]
29. [Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Katori H; Horiuchi C; Taguchi T; Yoshida T; Toth G
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():144-9. PubMed ID: 16897991
[TBL] [Abstract][Full Text] [Related]
30. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.
Scheulen ME; Saito K; Hilger RA; Mende B; Zergebel C; Strumberg D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):753-61. PubMed ID: 22020317
[TBL] [Abstract][Full Text] [Related]
31. [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
Yamamoto K; Imamura H; Furukawa H; Kishimoto T; Tanaka J; Oshiro R; Tatsuta M; Masutani S; Fukunaga M; Nakayama T; Takemoto H; Kondo M; Kamigaki S; Kawasaki T
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1748-51. PubMed ID: 16315929
[TBL] [Abstract][Full Text] [Related]
32. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
[TBL] [Abstract][Full Text] [Related]
33. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G
Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
[TBL] [Abstract][Full Text] [Related]
34. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma.
Ajani JA
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():117-20. PubMed ID: 16897985
[TBL] [Abstract][Full Text] [Related]
35. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
Hoff PM; Saad ED; Ajani JA; Lassere Y; Wenske C; Medgyesy D; Dwivedy S; Russo M; Pazdur R
Clin Cancer Res; 2003 Jan; 9(1):134-42. PubMed ID: 12538461
[TBL] [Abstract][Full Text] [Related]
36. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
[TBL] [Abstract][Full Text] [Related]
37. Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.
Sueda T; Kudo T; Sakai D; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Ezoe S; Matsumoto K; Doki Y; Mori M; Satoh T
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1321-4. PubMed ID: 25374410
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Oshima T; Yamada R; Hatori S; Kunisaki C; Imada T
Oncol Rep; 2006 Aug; 16(2):361-6. PubMed ID: 16820916
[TBL] [Abstract][Full Text] [Related]
39. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Cao S; Lu K; Tóth K; Slocum HK; Shirasaka T; Rustum YM
Clin Cancer Res; 1999 Feb; 5(2):267-74. PubMed ID: 10037174
[TBL] [Abstract][Full Text] [Related]
40. Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma.
Hisamitsu K; Tsujitani S; Yamaguchi K; Fukuda K; Konishi I; Kaibara N
Anticancer Res; 2004; 24(4):2495-501. PubMed ID: 15330204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
